Graphical Abstract Highlights d IFNa controls early viral dissemination, but does not affect long-term viral control d IFNb contributes to disruption of splenic architecture d Blocking IFNb improves T cell responses and accelerates clearance of persistent virus d IFNb blockade decreases rates of CD8a À DC infection, suggesting a mechanism of action
In Brief
Interferon a (IFNa) and IFNb utilize the same type I IFN receptor to regulate immune responses against microbial infection. Ng et al. show in vivo that IFNb and IFNa have differential roles in controlling a persistent viral infection, and that IFNb is the major factor responsible for causing viral persistence.
INTRODUCTION
Type I interferon (IFN-I) is a key element in the innate and adaptive response against host infection. Important functions of this family of cytokines include inducing an antimicrobial state, moderating innate immunity, and activating adaptive immunity. Although IFN-Is have generally been thought to be beneficial to the immune response against microbial infections, recent research has shown that IFN-I signaling may be detrimental in several pathogenic infections (Davidson et al., 2014; Harris et al., 2010; Mayer-Barber et al., 2014; Teijaro et al., 2013; Teles et al., 2013; Wilson et al., 2013) . Further, persistent viral infections such as HIV, SIV, and HCV are characterized by high interferon signatures suggesting that high levels of IFN-I signaling may play a role in disease pathogenesis (Bolen et al., 2013; Hardy et al., 2013; Sedaghat et al., 2008; Stylianou et al., 2000) . Previously, we reported that blockade of IFN-I signaling led to the accelerated clearance of persistent infection with the clone 13 (Cl-13) strain of lymphocytic choriomeningitis virus (LCMV) (Teijaro et al., 2013) . IFN-I signaling was associated with several factors that correlated with an immune-suppressive environment including the following: (1) induction of negative immune regulators (NIRs) interleukin-10 (IL-10) and programmed death ligand-1 (PD-L1), (2) disruption of splenic architecture, and (3) alteration of lymphocyte migration within the spleen. Blockade of IFN-I signaling corrected these defects, resulting in improved viral control. Although the IFN-I pathway was identified as a master regulatory pathway involved in persistent LCMV infection, it is unknown whether a specific species of IFN-I is responsible for these phenomena.
The IFN-I family consists of a dozen IFNa subtypes, IFNb, as well as IFNε, IFNu, and IFNk, which are induced after the detection of pathogens by pattern-recognition receptors. All IFN-I utilize the same heterodimeric receptor composed of IFNAR1 and IFNAR2; however, IFN-I subtypes have different signaling activities. Structured analysis has revealed that functional differences between IFNs are linked to their unique receptor binding strengths and dissociation rates, which combine to determine their ability to induce conformational change in the receptor. These ultimately control signal generation and downstream gene expression (Piehler et al., 2012; Thomas et al., 2011) . Importantly, IFNb has the highest binding affinity of the IFN-I family (Piehler et al., 2012) .
The LCMV Cl-13 virus induces a persistent viral infection in adult immunocompetent mice (Ahmed and Oldstone, 1988; Oldstone, 2002; Oldstone and Campbell, 2011) . During Cl-13 infection, IFNb is produced at high levels within the first 18-24 hr after infection. Comparatively, only a minimal amount is detected during infection with the Armstrong 53b (ARM) strain of LCMV, which only differs by three amino acids from Cl-13, but causes an acute infection (Bergthaler et al., 2010; Sullivan et al., 2011) . IFNa is detected in both Cl-13 and ARM infection; however, Cl-13 infection induces approximately 3-fold more IFNa (Teijaro et al., 2013) . The presence of robust levels of IFNb during infection with Cl-13 and its relative absence during ARM infection suggests that IFNb may play a major role in IFN-I mediated viral persistence. Based on these observations, we sought to determine the in vivo contribution of IFNb, as well as IFNa, to persistent LCMV infection using deletion mutants and antibody blockade. We found that early blockade of IFNb alone does (A-D) WT, ifnb À/À , and ifnar À/À mice were infected with 2 3 10 6 plaque-forming units (pfu) of LCMV Cl-13 virus. Tissues were harvested at 24 hpi to examine (A) virus localization in the spleen by immunofluorescent microscopy and (B-D) infection of DCs and macrophage/monocytes by flow cytometry.
(legend continued on next page) not alter early viral dissemination, but, most importantly, initiates events that lead to accelerated clearance of virus. Thus, we provide a biologic complement to the known physio-chemical difference between IFNa and IFNb signaling (Piehler et al., 2012; Thomas et al., 2011) .
RESULTS

IFNb Does Not Inhibit Early In Vivo Spread of Infection
To examine the establishment of infection, we used mice in which the ifnb gene had been deleted (ifnb À/À ) to ensure complete lack of signaling from IFNb. In wild-type (WT) mice, at 24 hr post-infection (hpi), virus is observed predominantly in the marginal zone. When IFN-I signaling is completely abrogated (ifnar À/À ), virus demonstrated spread beyond the marginal zone at 24 hpi ( Figure 1A ) corresponding with the inhibition of IFN-I anti-viral functions. Comparatively, ifnb À/À mice at 24 hpi did not exhibit differences in the localization of the virus. This same trend was also observed in the levels of infection in dendritic cell (DC) and macrophage/monocyte populations (Figures 1B and 1C) , which are both targets of Cl-13 infection. DCs and macrophage/monocyte populations in ifnar À/À mice exhibited (E-I) WT C57Bl/6 mice were intraperitoneally administered anti-IFNAR1, anti-IFNb, or IgG control antibody 1 day before infection with Cl-13 virus. (E) The number of infected CD8a+ DCs, CD8a À DCs, and macrophage/monocytes; (F) the proportion of the population infected; and (G) the relative level of LCMV nucleoprotein in infected cells as measured by mean fluorescent intensity were assessed at 24 hpi by flow cytometry. (H) Viral load in serum and spleen. The level of IFNa and IFNb (I) was measured in the serum by ELISA to test for possible alterations in expression due to antibody blockade. Data are presented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. Figure 2 . IFNb Contributes to Disruption of Splenic Architecture C57BL/6 mice were intraperitoneally given irrelevant IgG, anti-IFNb, or anti-IFNAR1 1 day before infection with Cl-13. At 5 and 9 dpi, spleens were harvested and either fluorescently stained for LCMV antigen (green) and MOMA-1 to define white pulp margins (red) (A-F), stained for H&E to examine histology (G-I), or immunofluorescently stained for CD3 to identify T cells (red) and ER-TR7 to delineate splenic stromal structure (green) (J-L). significantly higher levels of infection than WT mice. Cells that were infected also demonstrated higher numbers and higher levels of viral protein as assessed by levels of LCMV nucleoprotein (NP) staining ( Figures 1D-1G ). These two populations in ifnb À/À mice did not exhibit any increase in infection from WT mice as similar numbers and percent of infected cells were noted ( Figures 1B and 1C) , although there was an increase in the mean fluorescent intensity (MFI) of NP staining within infected DCs (ifnb À/À , 8,774.6 ± 2,414.6 versus WT, 4,903.2 ± 2,414.6; p > 0.005). To ensure that these observations were not due to abnormal development in the mutant mice, we also examined WT B6 mice treated with anti-IFNAR and anti-IFNb antibodies 1 day before infection. Here, the same observations were repeated. Anti-IFNb-treated mice did not exhibit any increase in the number or percentage of cells expressing viral antigen in the main subsets of DCs, CD8a+ and CD8aÀ, or macrophages/monocytes at 24 hpi (Figures 1D and 1E) . Nor did infected DCs of anti-IFNb-treated mice exhibit higher MFI levels of viral NP expression. Viral titers in total spleen tissue and serum at 24 and 48 hpi also did not demonstrate significant increases in titers in anti-IFNb compared to isotype controls, while anti-IFNAR treated mice exhibited significantly higher titers in both compartments ( Figure 1H ). The similarity in infection of antigen-presenting cells between IgG-treated and anti-IFNb-treated mice was likely due to the continued presence of IFNa, as these groups had equivalent levels in the serum ( Figure 1I ). As expected, when anti-IFNAR was used to block all IFN-I signaling, DCs and macrophage/monocytes were infected at higher rates in anti-IFNAR-treated mice compared to IgG-treated controls ( Figures 1E and 1F ). Examination of viral antigen in spleen tissues after the establishment of infection at 5 and 9 dpi (Figures 2A-2F ) also revealed little difference in general localization of virus. These data demonstrate that IFNb is not essential for early anti-viral activity and does not alter later viral localization, suggesting that IFNa is primarily responsible for the IFN-mediated anti-viral activity during early dissemination in vivo.
IFNb Contributes to Disruption of Splenic Architecture
Cl-13 infection results in the disorganization of secondary lymphoid tissue and disordered lymphocyte trafficking, factors that play a role in the observed globalized immune suppression (Berger et al., 1999; Mü ller et al., 2002; Odermatt et al., 1991; Tishon et al., 1993; Zeng et al., 2011) . This phenotype was readily apparent in the spleen as evidenced by the destruction of marginal zones and white pulp, which left little delineation between white pulp and red pulp shown by heavy hematoxylin staining across the entire spleen at 9 dpi ( Figure 2G ). Blockade of IFNAR signaling by antibody ( Figure 2I ; Teijaro et al., 2013) or gene deletion (data not shown) resulted in protection from this disorganization. Blockade of IFNb alone offered protection from Cl-13-mediated disorganization, with spleens from anti-IFNb-treated mice exhibiting more defined white pulp compared to control spleens ( Figure 2H ). Thus, aborting IFNb signaling results in a higher concentration of lymphocytes in the white pulp. This is further demonstrated by examining T cell zones, which are highly disturbed in normal Cl-13 infection ( Figure 2J ; Teijaro et al., 2013) . When IFNAR signaling is blocked, T cell zones and white pulp remain intact ( Figure 2L ; Teijaro et al., 2013) potentially maintaining efficient DC-T cell interactions to better facilitate T cell activation. Under anti-IFNb treatment, T cells remained localized at higher densities to the white pulp when compared to isotype controls ( Figure 2K ). Images depicted in Figure 2 are representative of spleen histology from 10 to 15 mice for each antibody treatment over three to four independent studies with analysis of greater than five independent areas of each splenic section.
IFNb Blockade Alters Virus-Specific Immune Responses
Previously, we showed that treatment of Cl-13-infected mice with anti-IFNAR antibody improved anti-LCMV CD4 T cell responses, but not CD8 T cell responses, at 5 and 9 dpi (Teijaro et al., 2013) . Here, we blocked IFNb alone, and at 9 dpi observed similar significant improvements in the number of LCMV glycoprotein (GP) 61-77 -specific IFNg + CD4 T cells and improvements in IFNg + TNFa + CD4 T cells ( Figure 3A) . Importantly, anti-IFNb-treated mice also exhibited increases in the number of anti-LCMV CD8 T cells at 9 dpi. The IFNb blockade resulted in a significant 2-fold increase in GP 33-41 -specific and NP 396-403 -specific IFNg + CD8 T cells over isotype controltreated mice and a significant 1.5-fold increase in IFNg + TNFa + CD8 T cells ( Figure 3B ). Although higher variability occurred when the number of GP 61-77 -specific CD4 T cells and GP 33-41specific CD8 T cells was assessed by tetramer staining, similar trends were observed ( Figure 3C ). The improvement in anti-LCMV T cell responses during IFNb blockade at these time points was not due to a reduction in immunodominant NIRs PD-L1 and IL-10, which have both been shown to contribute to Cl-13 persistence (Barber et al., 2006; Brooks et al., 2006 Brooks et al., , 2008 and are decreased in IFNAR blockade (Figures 3D and 3E; Teijaro et al., 2013) . There were no significant differences in cell surface expression of PD-L1 on antigen-presenting cells and splenic stromal cells of anti-IFNb-treated mice at 9 dpi or early on at 1 dpi (data not shown). Similarly, serum levels of IL-10 in anti-IFNb-treated mice were also comparable to controls at 9 dpi ( Figure 3E ) and at 1 dpi (data not shown). These differences were no longer significant at 15 ( Figure S1 ) and 40 dpi (data not shown). These data suggest that blocking IFNb signaling permits improved T cell activity, but as infection continues and antibody to IFNAR or IFNb wanes, T cell activity resembles control-treated mice.
IFNb Blockade, but Not IFNa Blockade, Accelerates Viral Clearance
To test if these observed differences mediated the contribution of IFNb to IFN-I-mediated viral persistence, we treated mice with anti-IFNb and followed the mice longitudinally to test viremia in sera and tissues over time. We also tested the involvement of IFNa by administering an anti-IFNa antibody that has been shown to neutralize six IFNa subtypes (A, 1, 4, 5, 11, and 13) . At 10 and 20 dpi ( Figure 3F ), blockade of either IFN alone did not exhibit any significant differences in viral titer. Anti-IFNARtreated mice exhibited slightly higher viral loads at 10 dpi and begin to decrease by 20 dpi as observed previously. At 30 dpi, viral titers decreased significantly in mice treated with anti-IFNb and anti-IFNAR compared to control mice, while no differences were observed in anti-IFNa-treated mice ( Figure 3F ). The decrease in serum viral load was greater in anti-IFNARtreated mice (1.8 log 10 ) compared to anti-IFNb-treated mice (0.8 log 10 ). At 40 dpi ( Figure 3G ) viral load in spleen, liver, lung, and serum was significantly reduced in anti-IFNb-and anti-IFNAR-treated mice compared to anti-IFNa-or isotype control-treated mice. Clearance in the anti-IFNb-treated mice was not due to an increase or decrease in IFNa production, as these mice had serum levels equivalent to control mice at 24 hpi when anti-IFNb antibody levels are highest ( Figure 1I ). Real-time PCR assessment of mRNA expression of the 12 IFNa subtypes also did not reveal any significant alterations in the proportion of each subtype expressed between anti-IFNb-and isotype control-treated mice (data not shown). Because the anti-IFNa antibody is only known to neutralize six subtypes of IFNa, we cannot rule out the participation of other IFNa subtypes in persistence. However, our results clearly show the involvement of IFNb in Cl-13 persistence.
Blockade of IFNb and IFN-I Signaling Decreases CD8a -DC Viral Load
Productive infection of DCs is necessary to maintain Cl-13 persistence (Popkin et al., 2011) , and, hence, a reduction of the population of DCs producing virus may contribute to early viral clearance. CD8a À DCs are the predominant subtype of conventional DCs that are infected (Ng and Oldstone, 2012) , although limited infection occurs in the smaller CD8a+ DC population. Accordingly, we examined both these DC populations to determine if IFN-I blockade altered infection of the conventional DC population. Since the peak serum viral load and peak of DC infection is between 7 and 10 dpi (Sevilla et al., 2003) , we measured DC infection at 7 dpi in anti-IFNband anti-IFNAR-treated mice to determine whether these mice better controlled infection in this population at a critical time point. At 7 dpi, infection of total splenocytes was slightly elevated in anti-IFNb-treated mice and significantly greater in anti-IFNAR-treated mice compared to isotype-treated mice ( Figure 4A ). This pattern was matched in the CD8a+ DC population ( Figure 4B ). However, CD8a À DC population, which makes up the majority of classical DC population, exhibited significantly lower percentages of infection in both anti-IFNb-and anti-IFNAR-treated mice ( Figure 4B ). To better ascertain whether the reduction in CD8a À DC infection was due to T cell responses, we examined the DC population at 4 dpi before T cell responses have peaked. DC infection at this earlier time point revealed similar trends to 7 dpi ( Figure S2 ). These data suggest that despite higher infection rates in the overall spleen, as well as serum, during IFNb and IFNAR blockade, the infection rates in CD8a À DC, a target population, are controlled, despite being higher at the initiation of infection (Figure 1) .
DISCUSSION
We, and others, previously established the IFN-I signaling pathway as a master regulator of viral persistence (Teijaro et al., 2013; Wilson et al., 2013) The spleens or antibody-treated mice infected with 2 3 10 6 pfu LCMV Cl-13 were harvested at 9 dpi to measure anti-LCMV T cell responses. (A) IFNg, TNFa, and IL-2 expression in CD4 T cells stimulated with LCMV CD4 epitope GP 61-77 . (B) IFNg, TNFa, and IL-2 expression in CD8 T cells stimulated with either GP 33-41 or NP 396-403 . (C) Number of GP 61-77 tetramer+ CD4 T cells and GP 33-41 tetramer+ CD8 T cells. (D) Cell surface expression of PD-L1 on antigen-presenting cells and stromal cells. (E) Levels of IL-10 in the serum were measured by ELISA. (F and G) IgG or antibody against IFNb, IFNa, or IFNAR were administered intraperitoneally 1 day before infection with 2 3 10 6 pfu LCMV Cl-13. (F) Viral load in the serum was assessed at 10, 20, and 30 dpi. (G) Viral load in spleen, liver, lung, and serum was quantitated at 40 dpi. Data are presented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. sets up a persistent infection, with the closely related ARM infection, which does not induce a persistent infection in immunocompetent mice, demonstrated that Cl-13 preferentially elicits higher levels of IFNb than ARM at 18-24 hpi. This suggested a role for IFNb in mediating persistent LCMV infection. Our study demonstrates that specific abrogation of IFNb recapitulates the accelerated viral clearance obtained by IFN-I receptor blockade. Total IFNa is elicited at > 10-fold-higher levels than IFNb at 24 hpi ( Figure 1I ; Teijaro et al., 2013) , but only abrogation of IFNb signaling altered the kinetics for clearance of Cl-13 infection. Thus, blockade of at least six subspecies of IFNa did not result in differences in infection clearance, restoration of splenic architecture, or T cell activity. Blockade of IFNb did not alter early viral dissemination, demonstrating that this cytokine is not vital to control early viral replication and complements other studies showing that early IFNa is important in managing viral spread (Sandler et al., 2014; Sullivan et al., 2015) . Though IFNb did not alter early viral dissemination, the influence of IFNb was markedly pronounced in later events. Anti-IFNb treatment significantly aborted lymphoid architecture disruption and dissolution of T cell zones, both hallmarks of persistent Cl-13 infection and other chronic viral infections. This indicates that IFNb signaling is detrimental to lymphoid structure and lymphocyte trafficking. Due to the strong association between lymphoid structure and T cell response, IFNb-generated changes likely impede efficient anti-viral T cell responses. Indeed, at 9 dpi when T cell exhaustion has already been established during Cl-13 infection, early anti-IFNb treatment generated an anti-LCMV CD4 response greater than those of control mice. IFNb blockade also generated greater CD8 T cell responses than isotype control-treated mice with greater numbers of IFNg+ CD8 T cells than observed with anti-IFNAR treatment, despite IL-10 and PD-L1 levels that were equivalent to control mice. Although increased T cell responses were transient, individual animals in the anti-IFNb group remained high at 15 dpi suggesting some level of disassociation between the dominant immune regulators IL-10 and PD-L1, which were not reduced by IFNb blockade. A similar example of vigorous anti-viral CD8 T cell responses in the presence of heightened IL-10 and PD-1/PD-L1 has recently been reported in acute LCMV infection of NZB mice (Baccala et al., 2014) . It is possible that other negative regulatory factors like TIM-3 (Jin et al., 2010; Sakuishi et al., 2011) or NK cell activity (Waggoner et al., 2012) were decreased and, thus, contributed to the increased T cell responses. Recently it has been described that IFNAR1 signaling on CD8 T cells targets them for NK cellmediated destruction (Xu et al., 2014) . Previous publications have also linked T cell suppression to antigen load (Mueller and Ahmed, 2009; Richter et al., 2012) . However, it is clear from our data and from previous studies of IFN-I blockade (Baccala et al., 2014; Teijaro et al., 2013; Wilson et al., 2013 ) that this association is not absolute and as shown here can be uncoupled by disrupting IFNb signaling.
Although blockade of IFNa using the monoclonal antibody TIF-3C5 did not elicit better control of viremia compared to IgG-isotype control-treated mice ( Figures 3F and 3G) , we cannot completely rule out some contribution by IFNa (or other forms of IFN-I) in viral persistence. The TIF-3C5 antibody neutralizes at least six subtypes of IFNa and, importantly, is able to neutralize significant amounts of IFNa in vivo to alter viral infection. TIF-3C5 antibody enhances susceptibility of both WT and IFNb À/À mice during infection with West Nile virus and results in increased lethality (K.C.F.S., H.M. Lazear, M.S. Diamond, and R.D.S., unpublished data). In our model, the antibody was administered 2 days before the peak of IFNa production (antibody given at À1 dpi with IFNa peak at 18-48 hpi). Hence, it is most likely that a majority of IFNa was neutralized between the 18 and 48 hpi when IFNa levels are highest. Further, even in the presence of high levels of IFNa, antibody to IFNb mediated viral control with a kinetic similar to that observed with anti-IFNAR antibody reinforcing the hypothesis that IFNa is not a major mediator of viral persistence.
The specific mechanism(s) by which IFN-I blockade, and specifically IFNb blockade, mediates viral clearance is uncertain. A component is likely dependent on CD4 T cells (Osokine et al., 2014; Teijaro et al., 2013) and DC infection (Popkin et al., 2011) . Our data suggest that control of infection in the DC is potentially an important factor in the early control of persistent infection observed in anti-IFNb-and anti-IFNAR-treated mice. CD8a À DCs, which compose $75% of the conventional DC population, are infected at decreased rates in anti-IFNb-and anti-IFNAR-treated mice at 7 dpi when serum viral load and total splenocyte infection rates are higher than isotype controls. At 4 dpi, infection in CD8a À DCs was lower in anti-IFNb-treated mice, but not anti-IFNAR-treated mice, which may be due to the much higher initial viral load in these mice. It is well established that DCs are a main target of Cl-13 infection Oldstone and Campbell, 2011; Sevilla et al., 2000 Sevilla et al., , 2003 , that functionally active LCMV-specific T cells can lyse virus-infected DCs (Borrow et al., 1995) , and that preventing or limiting productive infection of this population permits early resolution of the persistent infection (Popkin et al., 2011) . Consequently, decreasing rates of DC infection may lead to a decrease in viremia that is then more quickly controlled by the host immune response. A lower rate of DC infection would also result in a C57BL/6 mice were treated with IgG, anti-IFNb, or anti-IFNAR1 1 day before infection with Cl-13. At 7 dpi, the presence of LCMV NP was assessed by flow cytometry in the splenocytes (A) and CD8a+ and CD8a À DCs (B). Data are presented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. greater proportion of ''healthy'' DCs to initiate and maintain anti-LCMV T cell immunity as infected DCs have decreased cell surface expression of MHCII and co-stimulatory molecules CD80 and CD86 (Sevilla et al., 2003) . We are currently exploring twophoton analysis of DC-T cell interactions during Cl-13 infection and analyzing the effect of early abrogation of IFNb and IFN-I signaling.
Here we show that high expression of IFNb in vivo is advantageous to the virus LCMV. However, LCMV is able to block IFNb expression in vitro (Martínez-Sobrido et al., 2006) , and exogenous administration of IFN-I (both IFNb and IFNa5) 3-5 dpi can rescue CD8 T cell responses (Wang et al., 2012) . These dichotomous observations are likely due to an association between effect and magnitude and timing of signaling and in vitro conditions compared to in vivo studies. A recent study in SIV-infected macaques demonstrates that timing of IFN-I is an important factor in determining whether IFN-I signaling is beneficial or detrimental (Sandler et al., 2014) . Timing may involve not just the timing of the IFN-I family as a whole, but the timing of different subtypes. Each IFN-I subtype may have overlapping, but unique, windows during which the subtype's specific signaling may best generate a beneficial effect. The timing of early events is likely key as overcoming early innate signals is important to the establishment of persistence (Sullivan et al., 2015) . Priming mice with LCMV just before infection with CL-13 decreases the virus's ability to generate a battery of early cytokines, including IFNa, IFNb, and IL-10, as well as abrogating the virus's ability to persist. Signaling magnitude is also likely a factor as blockade of IFNAR1 via an antibody produces accelerated viral clearance (Teijaro et al., 2013; Wilson et al., 2013) , while deletion of the gene results in the inability to clear the virus. Coupled with IFN-I levels observed during ARM infection, these data suggest that there is a range of signaling below which signaling is not sufficient to generate immunity and above which the overwhelming signal becomes detrimental to immunity (i.e., zero/low signaling will not protect, while high levels of signaling will lead to downregulation of immunity and persistence).
In summary, there are more than a dozen different subtypes of IFN-I. Although there are certainly functional overlaps, it is unlikely that evolution would select for such a wide variety of IFN-I proteins unless each one fulfilled unique functions or roles during different types of immune responses. Our data indicate that of the IFN-I cytokines, IFNb is the major immune-suppressive cytokine during viral infection that inhibits viral clearance. There are several published examples of the immune-suppressive activity of IFNb. In multiple sclerosis, treatment with IFNb reduces the relapse rate, severity, and progression of this autoimmune disease (The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, 1995) by eliciting anti-inflammatory cytokines such as IL-10 (Byrnes et al., 2002; Rudick et al., 1996; Yong et al., 1998) and potentially restricting T cell proliferation (Yong et al., 1998) . In the murine model of cerebral malaria, IFNb treatment reduces disease severity and prolongs survival by reducing T cell recruitment to the brain (Morrell et al., 2011) . These examples coupled with the previous known functions of IFNb as an inducer of IFNa (Koch et al., 2005) , an anti-viral cytokine, and modulator of lymphocyte activity, serve to highlight IFNb's role as a master regulator of immune function.
The accumulation of data documenting immune-suppressive and detrimental effects of IFN-I indicate that not only are the effects of these cytokines complex, but careful mapping of their activity and receptor binding coupled with development of therapeutic molecules may also open new avenues for treatment of persistent viral infection and other disorders of T cell suppression or enhancement.
EXPERIMENTAL PROCEDURES
Mice and Viruses C57BL/6J male mice (6-8 weeks of age) were obtained from the rodent breeding colony at The Scripps Research Institute, while IFNb À/À and ifnar À/À mice were bred and maintained in the animal facility at the same institute. IFNb À/À were obtained from Dr. Eleanor Fish (University of Toronto). All mice were maintained in pathogen-free conditions, and handling conformed to the requirements of the NIH and The Scripps Research Institute Animal Research Committee. LCMV Cl-13 was grown, stored, and quantified according to previously published methods (Borrow et al., 1995) . Mice were infected by intravenous injection of 2 3 10 6 plaque-forming units (pfu) of virus. For quantification of viremia, blood was drawn from the retro-orbital sinus under isoflurane anesthesia. Serum was separated by low-speed centrifugation to remove red and white blood cells. Viral loads were then measured using plaque assays on VeroE6 cells (Ahmed et al., 1984) . Tissues (spleen, lung, liver, and kidney) were harvested from euthanized mice and frozen at À80 C. At the time of the assay, tissues were thawed, weighed, and homogenized in media to 10% w/v, clarified by low-speed centrifugation, and then utilized in plaque assays as previously described (Ahmed et al., 1984) . (Sheehan et al., 2006) , or a mouse IgG1 isotype control (clone MOPC21; Bio X Cell) 1 day prior to virus infection. Effective dose of anti-IFNb antibody was determined by titration for each new lot of antibody.
Antibody Treatments
Tissue Processing and Cell Surface Staining
Spleens were harvested at the indicated time points and processed into single-cell suspension through a 70-mm cell strainer (Corning Life Sciences) before lysing erythrocytes with ammonium chloride. Splenocytes were stained with anti-murine antibodies against markers for T cell subsets or macrophage and DC subsets (Text S1). For tetramer staining, splenocytes were incubated with either MHC class I tetramers for D b GP 33-41 and NP [396] [397] [398] [399] [400] [401] [402] [403] [404] or GP 61-77 (Text S1). Intracellular staining for the LCMV NP antigen was done by incubating the Alexa Fluor 488 conjugated VL-4 antibody (Bio X Cell; 1:100 dilution) in BD permeabilization solution (BD Biosciences, PharMingen) and analyzed by flow cytometry.
T Cell Cytokine Responses and Flow Cytometry
Splenocytes were stimulated with 2 mg/ml of MHC class I restricted LCMV-GP 33-41 and NP 396-404 peptide or 10 mg/ml of MHC class II restricted LCMV-GP 61-77 peptide (> 99% pure; American Peptide and The Scripps Research Institute, Center for Protein Science, La Jolla) for 1 hr in the absence of brefeldin A and then 5 hr in the presence of 4 mg/ml brefeldin A (Sigma, St. Louis) at 37 C. Cells were fixed, permeabilized with 2% saponin, and stained with antibodies to mouse IFN-g (XMG1.2), TNF-a (MP6-XT22), and IL-2 APC (JES6-5H4). Flow cytometric analysis was performed on a BD LSR II (Becton Dickinson), and data were analyzed using FlowJo (Tree Star). Absolute number of cells was determined by multiplying the frequency of specific cell populations by the total number of viable cells.
Tissue Staining and Imaging
For H&E staining, spleens were fixed overnight in formaldehyde/zinc fixative, paraffin embedded, sectioned, and stained using a standard H&E protocol.
For immunofluorescence, spleens were snap frozen on dry ice in OCT (Tissue-Tek) and stored at À80 C. Frozen sections (6 mm) were cut, fixed with 4% paraformaldehyde for 20 min, blocked with 10% FBS, and stained overnight at 4 C with either guinea pig antibody to LCMV (1:1,000 dilution), rabbit anti-mouse CD3 antibody (Abcam, 1:200), rat anti-mouse MOMA-1 antibody (Abcam, 1:200), or rat anti-ER-TR7 antibody (Abcam, 1:250). Tissues were washed, incubated at 1 hr with Alexa Fluor 488-conjugated antibody to guinea pig IgG (1:200, Invitrogen), Alexa Fluor 568-conjugated anti-rabbit IgG (1:200, Invitrogen), and Alexa Fluor 488-or 568-conjugated antibody to rat IgG (1:200, Invitrogen), washed, stained with 4,6-diamidino-2-phenylindole (DAPI), and mounted using Prolong Gold mounting medium (Life Technologies). Images were taken with a Zeiss Axiovert S100 immunofluorescence microscope fitted with an automated XY stage, an Axiocam color digital camera, and 53, 103, and 203 objectives.
Quantification of Cytokine and Chemokine Levels
IFN-I levels were quantified using VeriKine Mouse Interferon-Alpha and Interferon-Beta ELISA Kits (R&D Systems). IL-10 was quantified using the IL-10 Quantikine Kits (R&D Systems) according to the manufacturer's instructions.
Statistics
One-way ANOVA with Tukey's post test and Student's t test was calculated using GraphPad Prism 5, when appropriate, to determine significance, which was set at 5%.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and supplemental text and can be found with this article online at http://dx.doi.org/10.1016/j.chom. 2015.04.005.
